No Data
Dow Rallies 281 Points On Gains For Procter & Gamble, Travelers Shares
FDA recommends stopping the use of common decongestants in cold medicines, glaxosmithkline (GSK.US) and other companies may be affected.
The Food and Drug Administration (FDA) announced on Thursday that it has proposed to remove the oral phenylephrine commonly used in cold and cough syrups from the active ingredients of over-the-counter nasal decongestants and deemed it ineffective.
FDA Proposes Removing Oral Decongestant Phenylephrine From OTC Meds
The Procter & Gamble Company (PG): Steady Sales Growth and Market Leadership
Market Chatter: Unilever, Procter & Gamble Supply Chains Face Risks From Potential US Tariffs on Mexico
Express News | The USA FDA proposed to stop using the common decongestants in cold medicines.
No Data
No Data
No Data
